Merck and Moderna Announce Promising Trial Results for Personalized Cancer Vaccine
Merck and Moderna reported positive results from a late-stage clinical trial for a personalized mRNA-based cancer vaccine in melanoma patients.
Raleigh Durham, NC, August 19, 2026 —
Merck and Moderna have announced positive outcomes from a late-stage clinical trial evaluating a personalized mRNA-based cancer vaccine intended for patients with melanoma.
The trial focused on the efficacy of the investigational vaccine when used in conjunction with Merck’s established immunotherapy, Keytruda (pembrolizumab). This combination therapy aims to prevent the recurrence of melanoma, a type of skin cancer, following surgery.
While specific details regarding the trial’s quantitative results were not immediately available in the summary provided, the announcement indicates that the reported findings are considered positive by both pharmaceutical companies involved. The personalized nature of the vaccine means it is designed to target unique mutations within an individual patient’s tumor.
This collaborative effort between Merck and Moderna leverages Moderna’s mRNA platform technology, which has gained prominence in recent years, particularly with the development of COVID-19 vaccines. The application of mRNA technology to cancer treatment is an area of significant research and development within the pharmaceutical industry.
Further details on the trial’s data, including specific endpoints and statistical significance, are expected to be presented at upcoming medical conferences and potentially submitted for peer-reviewed publication.
The development marks a step forward in the exploration of personalized medicine for cancer treatment, with the potential to offer tailored therapeutic strategies to patients.
Story summarized from the original created by ABCNews on abc7.com, see more information here.
